Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
Recruiting
N/A
Interventional Study
Coronary Artery Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 30 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 500 (estimated)
- Sponsor
- Massachusetts General Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Current age 30-75 years
* Established primary care at Mass General Brigham with at least one visit in the last 2 years
Exclusion Criteria:
\- Currently taking LDL cholesterol- lowering medications, including statins
Contacts